戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              CCHF disease begins as a non-specific febrile illness wh
2                                              CCHF is caused by infection with the Crimean-Congo hemor
3                                              CCHF virus (CCHFV), a bunyavirus in the Nairovirus genus
4                                              CCHF virus (CCHFV, Nairoviridae) exhibits extensive geno
5                                              CCHF virus is endemic in parts of Africa, Asia, the Midd
6                                              CCHF-negative Hyalomma anatolicum tick pools were passag
7                            We identified 193 CCHF virus submission sets (4,754 entries), 78 Lassa vir
8 tion of convalescence following severe acute CCHF has been limited by the lack of suitable small anim
9 plication competent vaccine platform against CCHF infections.
10 del for studies of CCHF countermeasures, and CCHF-associated CNS disease.
11 y diverse virus strains were determined, and CCHF viruses were found to be highly variable with 20 an
12 en peptides representing Lassa virus GP2 and CCHF virus Gn cleavage sites suggests that amino acids f
13 eloped viraemia, high tissue viral loads and CCHF-induced disease, the NP + GPC vaccinated animals we
14 a ticks or by contact with infected animals, CCHF begins non-specifically but can rapidly progress to
15 ntly, there are no atomic structures for any CCHF virus proteins or for any Nairovirus proteins.
16 immunocompromised mice have been reported as CCHF disease models, but detailed characterization is la
17 ean-Congo hemorrhagic fever (CCHF) caused by CCHF virus (CCHFV) is one of the epidemic-prone diseases
18 CHF) is a severe disease of humans caused by CCHF virus (CCHFV), a biosafety level (BSL)-4 pathogen.
19  emerging tick-borne viral disease caused by CCHF virus (CCHFV).
20 proteins of Nigerian, Pakistani, and Chinese CCHF virus strains revealed two distinct protein regions
21 oms), consecutive sera (n = 25) of confirmed CCHF cases and control sera (n = 43).
22 ed in the former Soviet Union and the Congo, CCHF has rapidly spread across large sections of Europe,
23  may be very useful to diagnose convalescent CCHF cases especially in field studies.
24 lity in diagnosis with a focus on diagnosing CCHF in humans.
25 n when fed cholate-containing high fat diet (CCHF).
26 Africa, and can cause a hemorrhagic disease (CCHF) in humans with mortality rates as high as 60%.
27  ranging up to 70% based on several factors, CCHF is considered a dangerous emerging disease.
28  analog rescued disease in Cox2 MKO mice fed CCHF.
29                         Crimean Congo fever (CCHF) is a fatal disease with having fatality rate of up
30            Crimean-Congo haemorrhagic fever (CCHF) is a severe febrile illness transmitted by Hyalomm
31            Crimean-Congo haemorrhagic fever (CCHF) is a severe tick-borne illness with a wide geograp
32 ailable for Crimean-Congo hemorrhagic fever (CCHF) and their utility in diagnosis with a focus on dia
33             Crimean-Congo hemorrhagic fever (CCHF) caused by CCHF virus (CCHFV) is one of the epidemi
34 ic disease, Crimean-Congo hemorrhagic fever (CCHF) endemic in Africa, Asia, the Middle East, and Sout
35 outbreak of Crimean Congo hemorrhagic fever (CCHF) in Gujarat state, India.
36 he emerging Crimean-Congo hemorrhagic fever (CCHF) in Turkey the government is introducing thousands
37             Crimean-Congo hemorrhagic fever (CCHF) is a severe disease of humans caused by CCHF virus
38             Crimean-Congo hemorrhagic fever (CCHF) is a severe illness with high case fatality that o
39             Crimean-Congo hemorrhagic fever (CCHF) is a severe tick-borne febrile illness with wide g
40             Crimean-Congo hemorrhagic fever (CCHF) is a severe viral disease with high fatality rate.
41  causes the Crimean Congo Hemorrhagic Fever (CCHF) is a tick-borne pathogen of the Nairovirus genus,
42             Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral hemorrhagic disease seen exc
43             Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral infection caused by Crimean-
44             Crimean-Congo hemorrhagic fever (CCHF) is a widely distributed viral hemorrhagic fever ch
45             Crimean-Congo hemorrhagic fever (CCHF) is a widely distributed, viral, tickborne disease.
46  IMPORTANCE Crimean-Congo hemorrhagic fever (CCHF) is an emerging tick-borne viral disease caused by
47             Crimean-Congo hemorrhagic fever (CCHF) is the most widely distributed tick-borne viral in
48 ection with Crimean-Congo hemorrhagic fever (CCHF) virus (CCHFV) in human survivors is critical to th
49             Crimean-Congo hemorrhagic fever (CCHF) virus is a tick-borne member of the genus Nairovir
50             Crimean-Congo hemorrhagic fever (CCHF) virus is a tick-borne, negative-sense, single-stra
51             Crimean-Congo hemorrhagic fever (CCHF) virus is the cause of an important tick-borne dise
52 fected with Crimean-Congo hemorrhagic fever (CCHF) virus present with a wide clinical spectrum.
53  potential: Crimean-Congo Hemorrhagic Fever (CCHF) virus, Lassa virus, and Nipah virus.
54 gen causing Crimean-Congo hemorrhagic fever (CCHF), a severe fever disease.
55             Crimean-Congo hemorrhagic fever (CCHF), caused by Crimean-Congo hemorrhagic fever virus (
56 hikungunya, Crimean-Congo hemorrhagic fever [CCHF] virus, dengue, Ebola virus, Bundibugyo virus, Suda
57 rmore, there are no POC assays available for CCHF.
58     Strikingly, reported mortality rates for CCHF are extremely variable, ranging from 5% to 80% (Whi
59                      With fatality rates for CCHF ranging up to 70% based on several factors, CCHF is
60 ector is placing new populations at risk for CCHF, and no licensed vaccines or specific antivirals ex
61  a clinical severity scoring index (SSI) for CCHF patients and assess the effect of ribavirin and cor
62 rogression closely mimics hallmarks of human CCHF disease, making IFNAR(-/-) mice an excellent choice
63 investigations of the compound's efficacy in CCHF disease models.
64 on and disease have not been investigated in CCHF.
65               Hepatic injury is prevalent in CCHF and contributes to the severity and mortality of th
66 gical involvement have also been reported in CCHF.
67 contribution to the severe pathology seen in CCHF cases is largely unknown.
68 fatality rate, and no approved vaccine makes CCHF a threat to global health.
69 990 and Kosova Hoti that both yielded a mild CCHF disease state.
70 ic 4F mitigated disease in both the Cox2 MKO/CCHF and piroxicam-accelerated Il10-/- models of inflamm
71 cing intestinal inflammation in the Cox2 MKO/CCHF model.
72 nfirmed by expression of wild-type or mutant CCHF virus glycoproteins in CHO cells engineered to expr
73 y, our literature review found that 80.1% of CCHF, 86.6% of Lassa, and 87.5% of Nipah virus studies r
74 luding convalescence, an important aspect of CCHF disease that existing mouse models have been unsuit
75                                     Cases of CCHF are also being reported in new areas, indicating an
76                Furthermore, despite cases of CCHF being reported annually, the host and viral determi
77    Two hundred eighty-one confirmed cases of CCHF were included in the study.
78  cells (PBMCs) from a longitudinal cohort of CCHF patients during the acute phase of infection and af
79 00-fold greater sensitivity for detection of CCHF antibodies.
80 a fiber-optic biosensor for the detection of CCHF IgG antibodies.
81 talized patients who received a diagnosis of CCHF at the Infectious Diseases and Clinical Microbiolog
82                         Rapid diagnostics of CCHF is vital for appropriate clinical management and pr
83   A major limitation in the investigation of CCHF has been the lack of suitable small animal models.
84 tion in the CNS for future investigations of CCHF.
85     Recently, a cynomolgous macaque model of CCHF disease was developed.
86              We report here a mouse model of CCHF in which infected mice develop severe disease but u
87 CCHF have reported that the nucleoprotein of CCHF, being a pivotal protein in the replication process
88                            Many outbreaks of CCHF have been reported over the years.
89 iminate the acute and convalescent phases of CCHF was significantly higher with ELISA using rNP/rMLD
90 ropod-borne virus, the genomic plasticity of CCHF virus is surprisingly high.
91                   However, the prevalence of CCHF is not monitored in most of the endemic countries d
92                     Serological screening of CCHF is important and current ELISA use antigens prepare
93 epresent a novel lethal model for studies of CCHF countermeasures, and CCHF-associated CNS disease.
94 ated as a point-of-care diagnostic system of CCHF.
95 is is a critical gap in our understanding of CCHF, and investigation of convalescence following sever
96 alomma marginatum ticks, the best vectors of CCHF.
97                            Former studies on CCHF have reported that the nucleoprotein of CCHF, being
98 atopoietic CD34+ stem cells with low-passage CCHF virus strains isolated from human patients.
99  (82.1%), and 31 (91.2%) linked to published CCHF virus, Lassa virus, and Nipah virus studies, respec
100 es in adult, immunocompetent mice the severe CCHF observed in humans.
101                         We demonstrated that CCHF impaired intestinal barrier function and increased
102          These results strongly suggest that CCHF viruses (and other members of the genus Nairovirus)
103 e predicted polyprotein sequences of all the CCHF virus strains and closely resemble the tetrapeptide
104   The apparent lack of SKI-1 cleavage at the CCHF virus Gc RKPL site indicates that related proteases
105 e genus Nairovirus, family Bunyaviridae, the CCHF virus M genome RNA segment encodes the virus glycop
106 n of novel tick-borne viruses carried by the CCHF vector is an important step in the characterization
107 Unlike Hantavirus zinc fingers, however, the CCHF virus zinc fingers bind viral RNA and contain conti
108  only passed between animals and humans, the CCHF virus can also be transmitted from human to human w
109                     The amino termini of the CCHF virus (Matin strain) G2 and G1 proteins were establ
110                     Sequence analysis of the CCHF virus (Matin strain) M RNA segment revealed one maj
111      Here we report the NMR structure of the CCHF virus Gn cytoplasmic tail, residues 729-805.
112 ts provide insight into a likely role of the CCHF virus Gn zinc fingers in Nairovirus assembly.
113                 Caused by infection with the CCHF virus (CCHFV), cases are reported throughout Africa
114 ccines or specific antivirals exist to treat CCHF.
115  no approved vaccine or effective treatment, CCHF constitutes a threat against global health.
116 evaluated the fiber-optic biosensor with two CCHF patient sera.
117 tive immune responses in a cohort of Ugandan CCHF survivors via serial sampling over 6 years.
118 and in the intestinal tissue and plasma upon CCHF challenge.
119 artly driven by an historical lack of viable CCHF animal models.
120  pulse-chase analysis and/or reactivity with CCHF virus-specific polyclonal and antipeptide antibodie

 
Page Top